UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Act of 1934
Date of Report (Date of earliest event reported) - February 21, 2005
IMCOR PHARMACEUTICAL CO.
(Exact name as specified in its charter)
NEVADA | 0-23553 | 62-1742885 |
(State or other jurisdiction of | (Commission | (IRS Employer |
Incorporation or organization) | File Number) | Identification No.) |
| | |
| | |
6175 Lusk Boulevard | | |
San Diego, CA | | 92101 |
(Address of principal executive offices) | | (Zip Code) |
(858) 410-5601
(Registrants' telephone number, including area code)
(Former name or former address, if changed since last report)
Item 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.
On January 20, 2005, IMCOR Pharmaceutical Co. (the “Company”) held its 2004 Annual Meeting of Stockholders (the “Annual Meeting”) pursuant to a notice of meeting and Proxy Statement dated December 27, 2004. At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s articles of incorporation to effect a reverse split in the range of one-for-two- up to one-for-twenty, in the discretion of the Company’s Board of Directors.
The Company’s Board of Directors has determined that it is in the best interests of the Company to effect a one-for-twenty reverse split to be effective on March 4, 2005.
An amendment will be filed with Nevada Secretary of State to effect the reverse split on March 4, 2005. A copy of the Amendment is attached to this Form 8-K as Exhibit 3.1.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
| | (c) Exhibits. | |
| | | |
| | Exhibit Number | Description |
| | | |
| | 3.1 | Amendment to Articles of Incorporation. |
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed by the undersigned hereunto duly authorized.
| | | |
| | IMCOR PHARMACEUTICAL CO. |
|
|
|
| By: | /s/ Taffy J. Williams, Ph.D. |
| |
Taffy J. Williams, Ph.D. |
| | President and Chief Executive Officer |
| | |
| Dated: February 21, 2005 | |
| | |
